News

2016 Tribute Pharmaceuticals News Archive

Keyword Search
 
2015 | 2014
DateTitle 
02/01/16Tribute Announces Results of Shareholder Vote
MILTON, ONTARIO -- (Marketwired) -- 02/01/16 --         Tribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX)(OTCQX:TBUFF) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that it has received overwhelming shareholder approval of the previously announced plan of arrangement (the "Arrangement") with, among others, Aralez Pharmaceuticals Inc.... 
Printer Friendly Version
01/21/16Leading Independent Advisors Recommend That Tribute Shareholders Vote FOR the Transaction
MILTON, ONTARIO -- (Marketwired) -- 01/21/16 -- Tribute Pharmaceuticals Canada    Inc. (TSX VENTURE:TRX)(OTCQX:TBUFF) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the    acquisition, licensing, development and promotion of healthcare products in Canada    and the U.S., is pleased to announce that Institutional Shareholder Services    ("ISS") and Glass Lewis & Co. ("Glass    Lewis") have both recommended that Tribute shareholders vote FOR the specia... 
Printer Friendly Version
01/11/16Tribute Mails Materials in Connection With Special Meeting of Shareholders to Approve Transaction With POZEN and Encourages Shareholders to Vote
MILTON, ONTARIO -- (Marketwired) -- 01/11/16 -- Tribute Pharmaceuticals Canada    Inc. (TSX VENTURE:TRX)(OTCQX:TBUFF) ("Tribute" or    the "Company"), a specialty pharmaceutical    company with a primary focus on the acquisition, licensing, development and promotion    of healthcare products in Canada and the U.S., announced that the Management    Information Circular dated January 5, 2016 (the "Circular") and accompanying materials for Tribute's special    meeting to be held on February 1, 2016... 
Printer Friendly Version
01/04/16Tribute Pharmaceuticals Receives Notice of Allowance for Canadian Patent Expanding Cambia(R) Use in Migraine Treatment
MILTON, ONTARIO -- (Marketwired) -- 01/04/16 -- Tribute Pharmaceuticals Canada    Inc. (TSX VENTURE:TRX)(OTCQX:TBUFF) ("Tribute" or the "Company"), a Canadian    pharmaceutical company with a primary focus on the acquisition, licensing,    development and promotion of healthcare products in Canada and the U.S., today    announced that the Canadian Intellectual Property Office has issued a Notice of    Allowance for Canadian patent No. 2,632,375, entitled "Diclofenac Formulations and    Method of... 
Printer Friendly Version
Data provided by Nasdaq. Minimum 15 minutes delayed.